Form 4: ImmuCell Director Buys Shares Under 10b5-1 Plan

ImmuCell Director David Tomsche acquired 3,266 shares of common stock through direct and indirect ownership under a pre-arranged 10b5-1 plan.

Summary

• Director David Scott Tomsche of ImmuCell Corp (ICCC) acquired common stock on November 25, 2025.
• A total of 1,633 shares were acquired directly at a price of $4.76 per share.
• An additional 1,633 shares were acquired indirectly by his spouse at a price of $4.765 per share.
• These transactions were executed under a Rule 10b5-1 pre-arranged trading plan.
• Following these transactions, Tomsche directly owns 52,720 shares.
• Indirect ownership includes 4,740 shares held by his spouse and 73,927 shares held by the David Tomsche Living Trust.
• Total beneficial ownership after these transactions amounts to 131,387 shares.

Sentiment

Score: 7

Explanation: The director's purchase of company stock, even if modest and pre-planned, generally indicates a positive sentiment and confidence in the company's future prospects.

Positives

• A director increasing their stake in the company can signal confidence in future performance and alignment with shareholder interests.
• The transactions were executed under a Rule 10b5-1 plan, indicating a pre-planned investment strategy rather than a reaction to immediate news, which can be viewed as a disciplined approach to insider trading.

Future Outlook

This filing does not contain forward-looking statements or guidance; it reports a specific insider transaction.

Industry Context

Insider buying, particularly by a director, is often interpreted as a positive signal within the animal health or biotech industry, suggesting internal confidence in the company's prospects, irrespective of broader market conditions.

Comparison to Industry Standards

• Insider purchases are generally viewed favorably, as they align management's financial interests with those of shareholders, a common principle in corporate governance.
• The use of a Rule 10b5-1 plan is a standard and accepted practice for insiders to manage their stock transactions while adhering to securities laws and avoiding accusations of trading on material non-public information.
• The total value of the purchase (approximately $15,500) is relatively modest for a director, but still represents a direct investment in the company's equity.

Related Party Transactions

• Acquisition of 1,633 shares by the reporting person's spouse is considered an indirect beneficial ownership, a form of related party transaction in the context of beneficial ownership reporting.

Stakeholder Impact

• Shareholders may view the director's purchase as a positive signal, potentially increasing confidence in the stock and its future performance.

Key Dates

Recommendation

While a director's purchase of shares is generally a positive signal, the relatively modest size of this transaction and its execution under a pre-arranged 10b5-1 plan suggest it's part of a routine investment strategy rather than a strong, immediate bullish indicator. It reinforces a 'hold' position, indicating management's continued confidence without suggesting a significant new catalyst for a 'buy' recommendation.

Keywords

ImmuCell, ICCC, Insider Buy, Director Purchase, Stock Acquisition, Form 4, 10b5-1 Plan, Beneficial Ownership